ClinicalTrials.gg

Program

Evarucabgene Autoleucel

Also written as “NXC-201” and “NXC-201 CAR-T”.

Its studies are mostly in Amyloidosis · Immunoglobulin Light-chain Amyloidosis, led by Nexcella.

Furthest: phase 3, since Jul 12, 20262 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nexcella22 open or runningphase 3since Jul 12, 2026Oct 14, 2023Dec 2026phase 2 · NCT06097832

Also a collaborator on its studies: Immix Biopharma.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2023First study: phase 2 study in AmyloidosisFirst studyNCT06097832 · 45 enrolled · United States
  2. Jul 12, 2026Phase 3 study in AmyloidosisPhase 3 reachedNCT07709715 · 260 planned

Ahead

  1. Dec 2026Primary completion: phase 2 study in AmyloidosisNCT06097832
  2. Dec 2028Primary completion: phase 3 study in AmyloidosisNCT07709715

TargetBeta

TNFRSF17 →read by rule
“A preparation of autologous T-lymphocytes that have been transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) ”NCIt, by rule

Other programs on TNFRSF17

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
belantamab mafodotinruleGlaxoSmithKlinephase 325
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 37
anitocabtagene autoleucelruleGilead Sciencesphase 36
equecabtagene autoleucelrulenanjing-iaso-biotechnology-co-ltdphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytesrulecartesian-therapeuticsphase 26

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07709715Amyloidosis3Not yet recruitingDec 2028260
NCT06097832Amyloidosis · United States2Active, not recruitingDec 202645

How it is read

Names in the registry

  • “NXC-201”, 1 entry
  • “NXC-201 CAR-T”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.